Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CM-101 is a first-in-class monoclonal antibody that neutralizes the soluble protein CCL24, which is under phase 2 clinical development for the treatment of primary sclerosing cholangitis (PSC).
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
CM-101 is a first-in-class monoclonal antibody that neutralizes the soluble protein CCL24, which is under phase 2 clinical development for the treatment of primary sclerosing cholangitis (PSC).
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
CM-101 is a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
CM-101 is a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein with pro-fibrotic and pro-inflammatory effects. It is in development for the treatment of fibro-inflammatory disorders, including primary sclerosingcholangitis and systemic sclerosis.
Lead Product(s): CM-101
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: CM-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
CM-101 is a monoclonal antibody that neutralizes the soluble protein CCL24, a cytokine family member that can trigger self-reinforcing inflammatory and fibrotic pathways implicated in a number of serious progressive diseases.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
The analysis also showed that treatment with CM-101 interfered with core PSC pathways, including inhibiting ECM-related pathways and the recruitment and presence of monocytes and macrophages.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
The findings support the role of CCL24 as a potential therapeutic target, demonstrating elevated serum levels of CCL24 in patients with dcSSc. High CCL24 serum levels were correlated with disease activity and worse prognosis as reflected.
Lead Product(s): CM-101
Therapeutic Area: Immunology Product Name: CM-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
USFDA has cleared the company's INDA for CM-101, a first-in-class monoclonal antibody targeting the soluble protein CCL24, a novel and differentiated target that is overexpressed in fibrotic tissues.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2021